Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
October 28, 2025
Endocrinology Today — October 28, 2025
October 28, 2025
Obesity Today — October 28, 2025
October 28, 2025
Lucid Diligence Brief: Guardant Health and Zephyr AI partnership
October 28, 2025
Obesity Video Recap — October 28, 2025
October 27, 2025
Hematology Today — October 27, 2025
October 27, 2025
Oncology Video Recap — October 27, 2025
October 27, 2025
Oncology Today — October 27, 2025
October 27, 2025
AI in Healthcare and Digital Health Today—October 27, 2025
October 27, 2025
Lucid Diligence Brief: Novartis to acquire Avidity Biosciences
October 26, 2025
Lucid Diligence Brief: ENA Respiratory Series B for Intranasal INNA-051
October 25, 2025
Lucid Diligence Brief: Lilly to acquire Adverum Biotechnologies
October 24, 2025